Posted by Michael Wonder on 10 Jun 2024
Tagrisso granted priority review in the US for patients with unresectable, stage III EGFR mutated lung cancer
10 June 2024 - Decision based on LAURA Phase 3 trial results which extended median progression-free survival by more than three years.
AstraZeneca’s supplemental new drug application for has been accepted and granted priority review in the US for the treatment of adult patients with unresectable, stage III epidermal growth factor receptor mutated non-small cell lung cancer after chemoradiotherapy.
